Allogeneic Transplant: Durable Remissions in T-Cell Lymphomas Allogeneic Transplant: Durable Remissions in T-Cell Lymphomas

Five-year progression-free survival approached 40% and 5-year overall survival was over 50% in the study. Treatment-related mortality ranged from about 8% to 24%, depending on the donor type.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news